Relmada Therapeutics (RLMD) Financials

Relmada Therapeutics logo
$3.01 -0.60 (-16.62%)
Closing price 04:00 PM Eastern
Extended Trading
$3.13 +0.12 (+4.12%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Relmada Therapeutics

Annual Income Statements for Relmada Therapeutics

This table shows Relmada Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-21 -2.97 -6.29 -17 -59 -126 -157 -99 -80 -57
Consolidated Net Income / (Loss)
-21 -2.97 -6.29 -17 -59 -126 -157 -99 -80 -57
Net Income / (Loss) Continuing Operations
-21 -2.97 -6.29 -17 -59 -125 -159 -99 -80 -57
Total Pre-Tax Income
-21 -2.97 -6.29 -17 -59 -125 -159 -99 -80 -57
Total Operating Income
-17 -16 -7.22 -13 -61 -126 -161 -104 -84 -59
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
17 16 7.22 13 61 126 161 104 84 59
Selling, General & Admin Expense
9.23 10 5.93 5.70 25 35 48 49 38 32
Research & Development Expense
7.87 6.21 1.29 7.02 36 91 113 55 46 27
Total Other Income / (Expense), net
-3.70 13 0.93 -4.59 1.38 1.20 2.64 4.91 3.91 1.72
Interest & Investment Income
- - - - - - - 5.15 3.53 1.40
Other Income / (Expense), net
-3.71 13 0.93 -0.05 -0.02 0.00 -0.02 -0.24 0.38 0.32
Basic Earnings per Share
($2.09) ($0.26) ($0.52) ($2.74) ($3.81) ($7.16) ($5.30) ($3.28) ($2.65) ($1.45)
Weighted Average Basic Shares Outstanding
9.94M 11.60M 12.07M 9.24M 15.59M 17.55M 29.63M 30.10M 30.16M 39.48M
Diluted Earnings per Share
($2.09) ($0.26) ($0.52) ($2.74) ($3.81) - - ($3.28) ($2.65) ($1.45)
Weighted Average Diluted Shares Outstanding
9.94M 11.60M 12.07M 9.24M 15.59M 17.55M 30.10M 30.10M 30.16M 39.48M

Quarterly Income Statements for Relmada Therapeutics

This table shows Relmada Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 10 - - - 13
Net Income / (Loss) Attributable to Common Shareholders
-22 -18 -22 -19 -18 -9.87 -10 -20 -19 -13 -14
Consolidated Net Income / (Loss)
-22 -18 -22 -19 -18 -9.87 -10 -20 -19 -13 -14
Net Income / (Loss) Continuing Operations
-22 -18 -22 -19 -18 -9.87 -10 -20 -19 -13 -14
Total Pre-Tax Income
-22 -18 -22 -19 -18 -9.87 -10 -20 -19 -13 -14
Total Operating Income
-23 -19 -23 -19 -18 -10 -10 -20 -19 -15 -13
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
23 19 23 19 18 10 10 20 19 15 13
Selling, General & Admin Expense
9.68 8.10 12 8.08 6.27 7.40 6.29 12 11 6.62 3.88
Research & Development Expense
13 11 11 11 12 2.82 4.04 8.07 8.09 8.39 9.22
Total Other Income / (Expense), net
1.16 1.05 1.28 0.42 0.66 0.35 0.24 0.47 0.41 2.10 -0.77
Interest & Investment Income
1.06 0.96 0.86 0.65 0.44 0.32 0.25 0.39 0.96 2.30 2.27
Other Income / (Expense), net
0.10 0.09 0.43 -0.24 0.22 0.03 -0.01 0.08 -0.55 -0.20 -3.04
Basic Earnings per Share
($0.72) ($0.59) ($0.72) ($0.62) ($0.58) ($0.30) ($0.30) ($0.27) ($0.22) ($0.11) ($0.12)
Weighted Average Basic Shares Outstanding
30.13M 30.17M 30.17M 30.16M 30.41M 33.19M 33.19M 39.48M 86.60M 112.38M 112.44M
Diluted Earnings per Share
($0.72) ($0.59) ($0.72) ($0.62) ($0.58) ($0.30) ($0.30) ($0.27) ($0.22) ($0.11) ($0.12)
Weighted Average Diluted Shares Outstanding
30.13M 30.17M 30.17M 30.16M 30.41M 33.19M 33.19M 39.48M 86.60M 112.38M 112.44M
Weighted Average Basic & Diluted Shares Outstanding
30.17M 30.17M - 0.00 - - - 0.00 - 106.67M 106.69M

Annual Cash Flow Statements for Relmada Therapeutics

This table details how cash moves in and out of Relmada Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-3.09 -14 -6.79 34 -34 42 -39 -1.30 -0.23 -0.36
Net Cash From Operating Activities
-16 -13 -6.47 -12 -28 -92 -104 -52 -52 -46
Net Cash From Continuing Operating Activities
-16 -13 -6.47 -12 -28 -92 -104 -52 -52 -46
Net Income / (Loss) Continuing Operations
-21 -2.97 -6.29 -15 -59 -126 -157 -99 -80 -57
Consolidated Net Income / (Loss)
-21 -2.97 -6.29 -15 -59 -126 -157 -99 -80 -57
Non-Cash Adjustments To Reconcile Net Income
1.98 -12 0.70 2.77 21 42 43 44 30 16
Changes in Operating Assets and Liabilities, net
2.59 1.68 -0.96 0.14 11 -7.86 11 3.08 -1.58 -3.95
Net Cash From Investing Activities
-0.02 -0.56 -0.05 -80 -34 -54 20 50 52 -48
Net Cash From Continuing Investing Activities
-0.02 -0.56 -0.05 -80 -34 -54 20 50 52 -48
Purchase of Investments
- - - - -182 -223 -47 -90 -12 -84
Sale and/or Maturity of Investments
- - - - 148 169 67 141 64 36
Net Cash From Financing Activities
13 -0.26 -0.27 126 28 188 45 -0.10 -0.04 94
Net Cash From Continuing Financing Activities
13 -0.26 -0.27 126 28 188 45 -0.10 -0.04 94
Repurchase of Common Equity
- - - - - - - -0.10 -0.29 -0.07
Issuance of Common Equity
0.03 - - 126 20 188 43 0.00 0.00 94
Other Financing Activities, net
13 - - 0.00 8.79 0.00 2.34 - 0.25 0.00

Quarterly Cash Flow Statements for Relmada Therapeutics

This table details how cash moves in and out of Relmada Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-2.76 0.75 -0.60 2.37 -2.71 0.20 0.03 2.11 6.28 1.56 -5.61
Net Cash From Operating Activities
-13 -13 -17 -8.80 -18 -6.40 -6.72 -15 -15 -9.61 -13
Net Cash From Continuing Operating Activities
-13 -13 -17 -8.80 -18 -6.40 -6.72 -15 -15 -9.61 -13
Net Income / (Loss) Continuing Operations
-22 -18 -22 -19 -18 -9.87 -10 -20 -19 -13 -14
Consolidated Net Income / (Loss)
-22 -18 -22 -19 -18 -9.87 -10 -20 -19 -13 -14
Non-Cash Adjustments To Reconcile Net Income
8.19 7.13 7.82 6.67 4.26 3.42 4.05 3.83 4.18 2.45 2.77
Changes in Operating Assets and Liabilities, net
0.60 -2.62 -2.75 3.19 -4.77 0.05 -0.68 1.45 -0.20 0.86 -1.49
Net Cash From Investing Activities
10 14 16 11 15 6.68 6.75 -77 -135 18 6.95
Net Cash From Continuing Investing Activities
10 14 16 11 15 6.68 6.75 -77 -135 18 6.95
Purchase of Investments
-7.01 -1.30 -3.11 -0.65 -0.49 -0.32 -0.23 -83 -150 -25 -25
Sale and/or Maturity of Investments
17 15 19 12 16 7.00 6.99 5.86 14 42 32
Net Cash From Financing Activities
0.22 - -0.09 -0.17 0.00 -0.07 - 94 157 -6.42 0.02
Net Cash From Continuing Financing Activities
0.22 - -0.09 -0.17 0.00 -0.07 - 94 157 -6.42 0.02
Other Financing Activities, net
0.25 - - - 0.00 - - - 160 -160 0.02

Annual Balance Sheets for Relmada Therapeutics

This table presents Relmada Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2014 6/30/2015 6/30/2016 6/30/2017 6/30/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
26 24 10 2.84 10 118 223 153 98 46 94
Total Current Assets
26 24 9.30 2.47 9.98 118 223 153 98 46 94
Cash & Equivalents
26 22 8.50 1.71 9.22 2.50 - 5.40 4.09 3.86 3.50
Short-Term Investments
- - - - 0.00 115 167 143 92 41 90
Accounts Receivable
- - 0.23 0.23 0.18 - - 0.51 - - 0.00
Prepaid Expenses
0.18 1.50 0.57 0.47 0.52 0.90 11 4.04 1.19 0.89 0.98
Plant, Property, & Equipment, net
0.01 0.02 0.53 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.01 0.40 0.41 0.36 0.23 0.11 0.03 0.03 0.04 0.02 0.02
Other Noncurrent Operating Assets
0.01 0.40 0.41 0.02 0.03 0.03 0.03 0.03 0.04 0.02 0.02
Total Liabilities & Shareholders' Equity
26 24 10 2.84 10 118 223 153 98 46 94
Total Liabilities
27 16 3.20 1.38 2.61 13 15 12 12 10 7.49
Total Current Liabilities
27 16 3.06 1.38 2.61 13 15 12 12 10 6.43
Accounts Payable
0.75 0.84 1.26 0.53 0.92 8.35 11 5.26 3.51 4.13 1.57
Accrued Expenses
0.38 0.48 0.63 0.39 1.32 4.26 3.87 7.21 8.69 6.16 4.86
Total Noncurrent Liabilities
0.10 0.00 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.06
Other Noncurrent Operating Liabilities
0.10 0.00 0.14 - - - - - 0.00 0.00 1.06
Commitments & Contingencies
0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-1.11 8.81 7.04 1.46 7.61 106 208 140 85 36 87
Total Preferred & Common Equity
-1.11 8.81 7.04 1.46 7.61 106 208 140 85 36 87
Preferred Stock
0.00 0.00 0.00 0.00 0.00 - - 0.00 0.00 0.00 0.00
Total Common Equity
-1.11 8.81 7.04 1.46 7.61 106 208 140 85 36 87
Common Stock
54 85 86 87 119 285 513 603 646 676 785
Retained Earnings
-55 -76 -79 -85 -112 -179 -305 -462 -561 -641 -698

Quarterly Balance Sheets for Relmada Therapeutics

This table presents Relmada Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
122 109 84 71 56 28 21 15 235 219 205
Total Current Assets
122 109 84 71 56 28 21 15 235 219 205
Cash & Equivalents
14 6.70 1.34 2.09 1.48 1.15 1.35 1.38 9.78 11 5.72
Short-Term Investments
104 100 82 68 53 26 19 13 224 206 196
Accounts Receivable
0.00 0.00 - - - - - - - 0.01 0.01
Prepaid Expenses
3.47 2.83 0.75 0.54 1.58 0.60 0.47 0.97 1.38 1.30 2.92
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.03 0.05 0.04 0.05 0.02 0.02 0.02 0.02 0.02 0.02 0.25
Other Noncurrent Operating Assets
0.03 0.05 0.04 0.05 0.02 0.02 0.02 0.02 0.02 0.02 0.25
Total Liabilities & Shareholders' Equity
122 109 84 71 56 28 21 15 235 219 205
Total Liabilities
11 8.42 12 9.54 8.10 5.24 5.17 5.41 17 13 12
Total Current Liabilities
11 8.42 12 9.54 8.09 5.23 5.13 5.19 13 7.42 7.78
Accounts Payable
4.85 2.86 5.19 4.17 2.35 1.27 1.36 1.45 5.73 2.41 2.54
Accrued Expenses
5.85 5.57 7.17 5.36 5.74 3.97 3.77 3.74 7.16 5.01 5.24
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.22 3.74 5.08 3.78
Other Noncurrent Operating Liabilities
- - - - 0.01 0.01 - 0.22 3.74 5.08 3.78
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
111 101 72 61 48 22 16 9.47 219 207 194
Total Preferred & Common Equity
111 101 72 61 48 22 16 9.47 219 207 194
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
111 101 72 61 48 22 16 9.47 219 207 194
Common Stock
625 636 655 662 670 681 684 688 936 937 938
Retained Earnings
-514 -536 -583 -600 -622 -658 -668 -678 -717 -730 -744

Annual Metrics And Ratios for Relmada Therapeutics

This table displays calculated financial ratios and metrics derived from Relmada Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
53,743,024.00 12,019,162.00 12,039,912.00 12,548,870.00 33,256,987.00 16,241,526.00 17,530,830.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00
DEI Adjusted Shares Outstanding
53,743,024.00 12,019,162.00 12,039,912.00 12,548,870.00 33,256,987.00 16,241,526.00 17,530,830.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00
DEI Earnings Per Adjusted Shares Outstanding
-0.39 -0.25 -0.52 - -0.52 -3.66 -7.17 -5.22 -3.28 -2.66 -1.91
Growth Metrics
- - - - - - - - - - -
Profitability Metrics
- - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)
-12 -11 -5.05 -4.84 -8.91 -43 -88 -113 -73 -59 -41
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -85.04% -165.32% -47.82%
Earnings before Interest and Taxes (EBIT)
-21 -2.98 -6.29 -7.62 -13 -61 -126 -161 -104 -84 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-21 -2.92 -6.20 -6.59 -13 -61 -126 -161 -104 -84 -59
Valuation Ratios
- - - - - - - - - - -
Leverage & Solvency
- - - - - - - - - - -
Liquidity Ratios
- - - - - - - - - - -
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-25 -24 -6.26 -0.01 -13 -32 -96 -109 -70 -60 -44
Efficiency Ratios
- - - - - - - - - - -
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-13 -1.18 0.03 -4.81 -0.65 -12 -3.73 -7.89 -11 -9.39 -6.49
Increase / (Decrease) in Invested Capital
13 12 1.21 -4.84 4.16 -11 7.78 -4.16 -3.08 1.58 2.89
Book Value per Share
$0.16 $0.59 $0.12 ($0.44) $3.48 $6.50 $11.88 $4.67 $2.84 $1.18 $2.19
Tangible Book Value per Share
$0.16 $0.59 $0.12 ($0.44) $3.48 $6.50 $11.88 $4.67 $2.84 $1.18 $2.19
Total Capital
9.07 7.32 1.74 -2.57 116 106 208 140 85 36 87
Total Debt
0.26 0.27 0.28 2.94 0.11 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 2.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-22 -8.23 -1.43 0.70 -116 -117 -167 -148 -96 -45 -93
Capital Expenditures (CapEx)
0.02 0.56 0.05 0.01 85 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-14 -1.99 -0.34 -5.12 -0.85 -12 41 -7.92 -11 -9.40 -5.45
Debt-free Net Working Capital (DFNWC)
8.65 6.51 1.37 -2.88 116 105 208 140 85 36 88
Net Working Capital (NWC)
8.39 6.24 1.10 -3.17 115 105 208 140 85 36 88
Net Nonoperating Expense (NNE)
8.83 -8.38 1.23 4.12 8.41 17 38 44 26 21 16
Net Nonoperating Obligations (NNO)
-22 -8.23 -1.43 0.70 -116 -117 -212 -148 -96 -45 -93
Total Depreciation and Amortization (D&A)
0.01 0.05 0.09 1.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($2.09) ($0.26) ($0.52) ($0.71) ($0.69) ($3.81) ($7.16) ($5.30) ($3.28) ($2.65) ($1.45)
Adjusted Weighted Average Basic Shares Outstanding
10.81M 12.04M 12.55M 12.60M 39.58M 16.75M 29.37M 29.63M 30.10M 30.16M 39.48M
Adjusted Diluted Earnings per Share
($2.09) ($0.26) ($0.52) ($0.71) ($0.69) ($3.81) ($7.16) $0.00 $0.00 ($2.65) ($1.45)
Adjusted Weighted Average Diluted Shares Outstanding
10.81M 12.04M 12.55M 12.60M 39.58M 16.75M 29.37M 30.10M 30.17M 30.16M 39.48M
Adjusted Basic & Diluted Earnings per Share
($2.09) ($0.26) ($0.52) ($0.71) ($0.69) ($3.81) ($7.16) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
9.94M 11.60M 12.07M 12.55M 25.25M 15.59M 17.55M 30.10M 30.17M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-12 -11 -5.05 -4.84 -8.91 -43 -88 -113 -73 -59 -41
Debt Service Ratios
- - - - - - - - - - -
Payout Ratios
- - - - - - - - - - -

Quarterly Metrics And Ratios for Relmada Therapeutics

This table displays calculated financial ratios and metrics derived from Relmada Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 106,669,846.00
DEI Adjusted Shares Outstanding
30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 106,669,846.00
DEI Earnings Per Adjusted Shares Outstanding
-0.73 -0.59 -0.72 -0.62 -0.58 -0.33 -0.34 -0.66 -0.63 -0.43 -0.13
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Growth
16.87% 29.76% 3.18% 26.92% 21.34% 45.61% 54.22% - -11.18% -49.35% -56.08%
EBIT Growth
16.87% 29.76% 3.18% 26.92% 21.34% 45.61% 54.22% - -11.18% -49.35% -56.08%
NOPAT Growth
18.35% 27.69% -1.39% 28.90% 20.75% 45.69% 55.12% - -6.82% -46.86% -26.81%
Net Income Growth
17.07% 29.78% 1.25% 25.86% 19.56% 44.47% 53.55% - -8.50% -30.89% -37.37%
EPS Growth
0.00% 0.00% 1.37% 0.00% 19.44% 49.15% 58.33% - 62.07% 63.33% 60.00%
Operating Cash Flow Growth
21.01% 0.08% -43.21% 14.15% -38.59% 51.73% 59.64% - 16.60% -50.06% -87.23%
Free Cash Flow Firm Growth
49.98% 56.29% 46.17% 4.89% -71.32% -0.09% 38.63% - 84.70% 64.96% 44.07%
Invested Capital Growth
-65.88% -24.36% -17.18% 14.40% 60.05% 47.80% 31.91% - -229.63% -139.24% -89.69%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
13.40% 18.15% -20.56% 14.48% 6.79% 43.40% -1.48% - 1.20% 23.97% -6.05%
EBIT Q/Q Growth
13.40% 18.15% -20.56% 14.48% 6.79% 43.40% -1.48% - 1.20% 23.97% -6.05%
NOPAT Q/Q Growth
14.32% 18.14% -22.27% 17.09% 4.49% 43.90% -1.04% - 4.29% 22.87% 12.75%
Net Income Q/Q Growth
13.26% 18.60% -22.28% 14.13% 5.88% 43.81% -2.28% - 4.11% 32.22% -7.34%
EPS Q/Q Growth
0.00% 18.06% -22.03% 0.00% 0.00% 48.28% 0.00% - 18.52% 50.00% -9.09%
Operating Cash Flow Q/Q Growth
-27.19% -1.74% -25.59% 47.17% -105.32% 64.57% -5.00% - -3.23% 36.24% -31.01%
Free Cash Flow Firm Q/Q Growth
26.77% 0.67% -32.69% 1.47% -31.92% 41.97% 18.63% - 82.41% -32.91% -29.90%
Invested Capital Q/Q Growth
-5.47% 22.66% 27.42% -44.59% 50.78% -1.07% 5.33% - -134.52% 26.64% 24.94%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent
95.39% 94.86% 96.21% 96.61% 97.55% 96.84% 97.61% - 95.20% 84.87% 85.90%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
-95.48% -100.40% -116.60% -132.33% -160.26% -175.12% -196.79% - -48.83% -55.66% -64.66%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-95.48% -100.40% -116.60% -132.33% -160.26% -175.12% -196.79% - -48.83% -55.66% -64.66%
Return on Equity Simple (ROE_SIMPLE)
-130.89% 0.00% 0.00% 0.00% -337.38% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-16 -13 -16 -13 -13 -7.15 -7.23 -14 -14 -11 -9.17
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-5.31% -4.86% -7.01% -7.51% -8.69% -5.96% -8.42% - -4.16% -2.02% -4.35%
Return On Investment Capital (ROIC_SIMPLE)
-22.33% -21.42% -33.82% -37.59% -56.83% -44.86% -76.37% -16.45% -6.23% -5.09% -4.73%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-23 -19 -23 -19 -18 -10 -10 -20 -20 -15 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-23 -19 -23 -19 -18 -10 -10 -20 -20 -15 -16
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.94 1.47 2.05 0.44 0.37 1.25 7.05 - 2.76 3.76 2.19
Price to Tangible Book Value (P/TBV)
1.94 1.47 2.05 0.44 0.37 1.25 7.05 - 2.76 3.76 2.19
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage
-1.09 -1.09 -1.08 -1.17 -1.17 -1.18 -1.19 - -1.08 -1.07 -1.06
Leverage Ratio
1.11 1.12 1.11 1.19 1.19 1.19 1.24 - 1.09 1.08 1.08
Compound Leverage Factor
1.06 1.06 1.07 1.15 1.16 1.15 1.21 - 1.04 0.92 0.93
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score
-2.74 -5.97 -8.70 -19.13 -33.54 -42.68 -57.96 - 18.33 33.59 17.82
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
6.82 7.44 6.89 4.45 5.29 4.11 2.86 - 18.26 29.52 26.37
Quick Ratio
6.76 7.39 6.69 4.36 5.17 4.02 2.68 - 18.15 29.34 26.00
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-11 -11 -15 -15 -20 -11 -9.30 -17 -3.01 -4.00 -5.20
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-12 -8.95 -6.49 -9.39 -4.62 -4.67 -4.42 -6.49 -15 -11 -8.39
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-4.59 -1.75 -0.95 1.58 6.95 4.28 2.07 2.89 -11 -6.50 -3.97
Enterprise Value (EV)
57 20 44 -29 -19 -0.69 53 - 369 560 222
Market Capitalization
140 91 98 16 8.21 20 67 - 603 778 424
Book Value per Share
$2.39 $2.04 $1.58 $1.18 $0.74 $0.48 $0.29 $2.19 $2.53 $1.84 $1.82
Tangible Book Value per Share
$2.39 $2.04 $1.58 $1.18 $0.74 $0.48 $0.29 $2.19 $2.53 $1.84 $1.82
Total Capital
72 61 48 36 22 16 9.47 87 219 207 194
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-84 -70 -54 -45 -27 -21 -14 -93 -234 -218 -202
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-12 -9.00 -6.50 -9.40 -4.64 -4.66 -4.22 -5.45 -12 -6.11 -4.85
Debt-free Net Working Capital (DFNWC)
72 61 48 36 22 16 9.66 88 222 212 197
Net Working Capital (NWC)
72 61 48 36 22 16 9.66 88 222 212 197
Net Nonoperating Expense (NNE)
5.74 4.59 5.62 5.30 4.81 2.71 2.86 5.63 5.43 2.41 4.69
Net Nonoperating Obligations (NNO)
-84 -70 -54 -45 -27 -21 -14 -93 -234 -218 -202
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.72) ($0.59) ($0.72) ($0.62) ($0.58) ($0.30) ($0.30) ($0.27) ($0.22) ($0.11) ($0.12)
Adjusted Weighted Average Basic Shares Outstanding
30.13M 30.17M 30.17M 30.16M 30.41M 33.19M 33.19M 39.48M 86.60M 112.38M 112.44M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($0.72) ($0.62) ($0.58) ($0.30) ($0.30) ($0.27) ($0.22) ($0.11) ($0.12)
Adjusted Weighted Average Diluted Shares Outstanding
30.17M 30.17M 30.17M 30.16M 30.41M 33.19M 33.19M 39.48M 86.60M 112.38M 112.44M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
30.17M 30.17M 0.00 0.00 0.00 0.00 0.00 0.00 0.00 106.67M 106.69M
Normalized Net Operating Profit after Tax (NOPAT)
-16 -13 -16 -13 -13 -7.15 -7.23 -14 -14 -11 -9.17
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -0.36% -0.35% 0.00% 0.00% - -5.94% -16.07% -15.15%

Financials Breakdown Chart

Key Financial Trends

Relmada Therapeutics remains a pre-revenue biotechnology company. Total revenue has been reported at $0 in every income statement period provided, so the company continues to rely on cash reserves, investment income and financing activity to fund operations.

The latest quarter showed some improvement in operating performance. Q2 2026 operating expenses declined to $15.0 million from $19.5 million in Q1 2026 and $20.3 million in Q4 2025. The quarterly net loss narrowed to $12.9 million, compared with $19.1 million in Q1 2026 and $19.9 million in Q4 2025. However, the loss remained larger than the $9.9 million reported in Q2 2025.

Relmada’s balance sheet provides a substantial financial cushion, although that cushion has declined over time. Cash and short-term investments totaled approximately $219.7 million at June 30, 2026, compared with $235.2 million at March 31, 2026 and $109.1 million at September 30, 2023. The company reported only $12.5 million of total liabilities, giving it a strong liquidity position relative to its obligations.

  • Strong liquidity: Cash and short-term investments of approximately $219.7 million substantially exceeded total liabilities of $12.5 million at the end of Q2 2026.
  • Lower quarterly operating burn: Cash used in operating activities improved to $9.6 million in Q2 2026 from $15.1 million in Q1 2026 and $14.6 million in Q4 2025.
  • Improving expense control: Selling, general and administrative expense fell to $6.6 million in Q2 2026 from $11.4 million in Q1 2026 and $12.3 million in Q4 2025.
  • Interest income is helping offset losses: Interest and investment income increased to $2.3 million in Q2 2026 from $1.0 million in Q1 and $0.4 million in Q4 2025.
  • Potentially extended runway: Based on Q2 2026 operating cash usage, the company’s cash and investments could support several years of operations, but the actual runway will depend on clinical spending, trial results, financing activity and investment values.
  • Investment portfolio drives cash fluctuations: Relmada regularly purchases and sells short-term investments. Q2 investing activities generated $17.6 million of net cash, while Q1 investing activities used $135.2 million, making quarter-to-quarter cash changes difficult to interpret as operating trends.
  • No operating revenue: Relmada has not yet demonstrated commercial revenue, and its operating losses remain dependent on the future success and commercialization of its drug-development pipeline.
  • Persistent net losses: The company has reported recurring quarterly losses, including $12.9 million in Q2 2026, and retained earnings were negative $730.2 million at June 30, 2026.
  • Cash reserves are declining over the longer term: Cash and short-term investments fell from approximately $109.1 million at September 30, 2023 to $70.9 million at June 30, 2024, before financing activity lifted them above $200 million in 2026. Continued operating losses could reduce this balance again.
  • Significant share-count growth: Weighted-average basic shares outstanding rose from approximately 30.2 million in Q1 2024 to 112.4 million in Q2 2026, creating substantial dilution risk for existing shareholders.

Overall, Relmada’s financial position is supported by a large investment portfolio and relatively low liabilities, while recent expense reductions and a lower operating cash burn are constructive. The primary risks remain the absence of revenue, continued dependence on clinical and financing outcomes, declining retained earnings and the substantial increase in shares outstanding.

11/17/26 06:43 PM ETAI Generated. May Contain Errors.

Relmada Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Relmada Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Relmada Therapeutics' net income appears to be on a downward trend, with a most recent value of -$57.39 million in 2025, falling from -$20.80 million in 2015. The previous period was -$79.98 million in 2024. Find out what analysts predict for Relmada Therapeutics in the coming months.

Relmada Therapeutics' total operating income in 2025 was -$59.10 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $59.10 million

Over the last 10 years, Relmada Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 13 quarters, Relmada Therapeutics' cash and equivalents has ranged from $1.15 million in Q1 2025 to $14.47 million in Q2 2023, and is currently $5.72 million as of their latest financial filing in Q3 2026.

Relmada Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2015.

Over the last 10 years, Relmada Therapeutics' book value per share changed from 0.16 in 2015 to 2.19 in 2025, a change of 1,237.0%.



Financial statements for NASDAQ:RLMD last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners